Lantheus Holdings, Inc.
Bedford, MA Lantheus Holdings, Inc.
- UEI
- XKLLNAJB6LJ6
- CAGE
- 7ZG90
- Primary NAICS
- 325412 Pharmaceutical Preparation Manufacturing
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Lantheus Holdings, Inc.
XKLLNAJB6LJ6
- Progenics Pharmaceuticals Inc. YLYKVRPCTCR3
-
Lantheus Holdings, Inc.
XKLLNAJB6LJ6
- SAM.gov registration date
- Physical address
- 201 Burlington Rd, Bedford, MA 01730, USA
- Website
- lantheus.com
- Founded
- 1956
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Pylarify | Veterans Integrated Service Network 6 | $379,822 |
About Lantheus Holdings, Inc.
Lantheus Holdings, Inc. is a for-profit pharmaceutical company specializing in the development, manufacturing, and distribution of diagnostic medical imaging agents and radiopharmaceutical products for federal healthcare providers. Operating through its divisions including Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals Inc., the company serves as a critical supplier of specialized nuclear medicine supplies and diagnostic imaging products to the federal government. The company's core business focuses on providing innovative diagnostic and therapeutic agents, particularly for oncology applications, positioning it as a leading vendor in the federal healthcare sector for radiopharmaceutical procurement.
Lantheus Holdings, Inc. and its subsidiaries have received numerous federal contract awards totaling millions of dollars for the supply of radiopharmaceutical products and medical imaging equipment. The primary product supplied through these contracts is PYLARIFY (piflufolastat F-18), a radioactive diagnostic imaging agent used in positron emission tomography (PET) scans for prostate cancer detection and localization. Additional products include Technetium-99m generators, Xenon-133 gas, and other specialized nuclear medicine supplies. The company's federal contracts have been awarded primarily by the Department of Veterans Affairs through various Veterans Integrated Service Networks (VISN 1-23), the Defense Health Agency, the National Institutes of Health Clinical Center, and the Department of the Army. Contract types have included delivery orders, blanket purchase agreement calls, and purchase orders, with pricing structured as firm fixed-price arrangements. The majority of awards have not utilized set-aside designations, though the company has received several contracts designated as total small business set-asides with individual contract values ranging from under $20,000 to over $9 million. Delivery performance locations are primarily centered at the company's facility in North Billerica, Massachusetts, though some contracts specify performance at other locations including Fort Sam Houston, Texas and Loma Linda, California.
Lantheus Holdings, Inc. maintains substantial indefinite delivery vehicles with federal agencies that facilitate efficient procurement of its products across multiple facilities and service networks. The company holds a major Federal Supply Schedule contract under the Pharmaceuticals and Drugs (FSS-61-IB) with the General Services Administration that carries a ceiling value of approximately $290 million extending through March 31, 2030, serving as the parent master vehicle for numerous task orders and delivery orders issued by the Veterans Health Administration and Defense Health Agency. Additionally, Lantheus Medical Imaging, Inc. maintains multiple blanket purchase agreements with the Defense Health Agency valued between $1 million and $6.5 million for the supply of radiopharmaceuticals and nuclear medicine supplies through July 2028. Through these IDVs, various Veterans Integrated Service Networks have issued task orders for PYLARIFY ranging from under $15,000 to over $9 million, with completion dates extending through 2030. The NIH Clinical Center and Defense Health Agency have also issued delivery orders and BPA calls against these master vehicles to support medical imaging programs at federal medical facilities nationwide. The contract structures enable government healthcare providers to streamline procurement of critical radiopharmaceutical products while maintaining cost certainty through firm fixed-price arrangements, supporting comprehensive oncology diagnostic imaging programs across the federal healthcare system.
Quick answers
What is Lantheus Holdings, Inc.'s UEI?
Lantheus Holdings, Inc.'s Unique Entity ID (UEI) in SAM.gov is XKLLNAJB6LJ6.
What is Lantheus Holdings, Inc.'s CAGE code?
Lantheus Holdings, Inc.'s CAGE code is 7ZG90.
What is Lantheus Holdings, Inc.'s primary NAICS code?
Lantheus Holdings, Inc.'s primary NAICS code is 325412 (Pharmaceutical Preparation Manufacturing).
Where is Lantheus Holdings, Inc. located?
Lantheus Holdings, Inc.'s physical address in SAM.gov is 201 Burlington Rd, Bedford, MA 01730, USA.
Is Lantheus Holdings, Inc. registered in SAM.gov?
Yes. Lantheus Holdings, Inc.'s SAM.gov registration is active through January 7, 2027.
What is Lantheus Holdings, Inc.'s most recent federal award?
Lantheus Holdings, Inc.'s most recent federal contract award is Pylarify (36C24622P0024), from Veterans Integrated Service Network 6, on October 1, 2021.
On GovTribe
See Lantheus Holdings, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors